PCM
SNDX icon

Pavaki Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Pavaki Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Hold
60,000
– – 0.46% 43
2026
Q1 		$1.4M Hold
60,000
– – 0.6% 38
2025
Q4 		$1.26M Buy
+60,000
New +$1.05M 0.49% 40

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Pavaki Capital Management's SNDX Position: Q2 2026 in Review

Pavaki Capital Management held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 60,000 shares worth $1.31M. The position accounts for 0.46% of the portfolio, ranked #43.

Pavaki Capital Management first reported a position in SNDX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.4M in Q1 2026. 218 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Pavaki Capital Management held 60,000 shares of Syndax Pharmaceuticals worth $1.31M as of Q2 2026.
  • Pavaki Capital Management left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
  • Syndax Pharmaceuticals made up 0.46% of Pavaki Capital Management's portfolio in Q2 2026, its #43 holding.
  • Pavaki Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Pavaki Capital Management's Syndax Pharmaceuticals position peaked at $1.4M in Q1 2026.
  • 218 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.